Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

Blood (2025) 146 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2025-LBA-4

Published: 2025

Journal Articles

Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial

Katharine Lewis, Piers Blombery, Nagendra Prasad Sungala, Pratyush Giri, Tamara Marconi, Tara Cochrane, Roslyn Francis, Sze-Ting Lee, Chun Kei Kris Ma, Vinay Vanguru, Kate Manos, Colm Keane, Sally Hunter, Melinda Burgess, Sushmitha Kannan, Julia Carlson, Mannu Walia, Belinda Butcher, Chan Cheah

Blood (2025) 146 (Supplement 1): 1016.

https://doi.org/10.1182/blood-2025-1016

Published: 2025

Journal Articles

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Sean McKeague, Thomas Lew, LeiShong Lau, Philip Thompson, Ashley Whitechurch, Dennis Carney, Gemma Reynolds, Piers Blombery, John Seymour, Andrew Roberts, Mary Ann Anderson

Blood (2025) 146 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2025-2130

Published: 2025

Journal Articles

Integrative analysis of the tumour immune microenvironment of breast implant-associated anaplastic large cell lymphoma using multi-omics

Criselle Dsouza, Niko Thio, Ruiqing Zhu, Harini Desilva, Piers Blombery, Ella Thompson, Anand Deva, H. Miles Prince, Paul Neeson

Blood (2025) 146 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2025-3563

Published: 2025

Journal Articles

Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma

Kate Manos, Melinda Burgess, Geoffrey Chong, Sze-Ting Lee, Charmaine Smith, William Renwick, Sarah Kempe, Valentine Murigneux, Rakin Chowdhury, Piers Blombery, Niles Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Allison Barraclough, Joel Wight, Colm Keane, Eliza Hawkes

Blood (2025) 146 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2025-3306

Published: 2025

Journal Articles

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors

Constantine S. Tam, Shalini Balendran, Piers Blombery

Blood (2025) 145 (10): 1005–1009.

https://doi.org/10.1182/blood.2024026672

Published: 2025

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Chan Y. Cheah, Amanda Jane Johnston, Joel Wight, Piers Blombery, Katharine L. Lewis, Rory Bennett, Jing Xie, Stella Vlahos, Joyce Gonzales, Sally Binks, John F. Seymour

Blood (2024) 144 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2024-199108

Published: 2024

Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 51.

https://doi.org/10.1182/blood-2024-201145

Published: 2024

Journal Articles

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

Blood (2024) 144 (Supplement 1): 303.

https://doi.org/10.1182/blood-2024-209378

Published: 2024

Journal Articles

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Zhi Han Yeoh, Ing Soo Tiong, Mark R Dowling, Hamish W Scott, Nicole O'Leary, Samantha van der Linde, Tamia Nguyen, Simon J Harrison, Ashish Bajel, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 653.

https://doi.org/10.1182/blood-2024-204494

Published: 2024

Journal Articles

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Blood (2024) 144 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2024-208841

Published: 2024

Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Blood (2024) 144 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2024-208727

Published: 2024

Journal Articles

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Lucy C Fox, Nicole Den Elzen, Erin Goode, Kelsey Man, Lin Cheng, Stephanie Best, Jillian Francis, Laura Barth, Paul James, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2024) 144 (Supplement 1): 5015.

https://doi.org/10.1182/blood-2024-202704

Published: 2024

Journal Articles

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Blood (2024) 144 (Supplement 1): 582.

https://doi.org/10.1182/blood-2024-204930

Published: 2024

Journal Articles

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma

Katharine L. Lewis, Pratyush Giri, Tamara Marconi, Piers Blombery, Colm Keane, Nagendra Prasad Sungala, Tara Cochrane, Chun Kei Kris Ma, Vinay Vanguru, Kate Manos, Roslyn Francis, Mannu Walia, Julia Carlson, Belinda E Butcher, Chan Y. Cheah

Blood (2024) 144 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2024-204317

Published: 2024

Journal Articles

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, Edward Ayoub, Marietta Truger, Manja Meggendorfer, Miriam Lenk, Gregor Hoermann, Stephan Hutter, Heiko Müller, Wencke Walter, Martha-Lena Müller, Niroshan Nadarajah, Piers Blombery, Ulrich Keller, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach

Blood (2024) 143 (12): 1139–1156.

https://doi.org/10.1182/blood.2023021199

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Rithin Nedumannil, Tal Karmi, Piers Blombery, Charlotte Hughes, Jeff Szer, David S. Ritchie, Lynette C.Y. Chee

Blood (2023) 142 (Supplement 1): 629.

https://doi.org/10.1182/blood-2023-174666

Published: 2023

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Lucy C. Fox, Nicole Den Elzen, Laura Barth, Kelsey Man, Paul James, Jillian Francis, Lin Cheng, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2023) 142 (Supplement 1): 369.

https://doi.org/10.1182/blood-2023-177593

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Integrative analysis of the tumour immune microenvironment of breast implant-associated anaplastic large cell lymphoma using multi-omics

Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only